№ files_lp_4_process_1_27856
File format: docx
Character count: 4814
File size: 26 KB
Form filed with the SEC reporting acquisition and vesting schedule of stock and options held by an executive, including dates, quantities, and legal acknowledgment.
Year:
2026
Jurisdiction:
United States
Company:
Milestone Pharmaceuticals Inc.
Ticker:
MIST
Form Type:
Form 4
Reporting Person:
Nelson Jeffrey Edward
Position:
Chief Operating Officer
Transaction Date:
02/02/2026
Securities Involved:
Common Stock, Stock Options, Restricted Stock Units
Number of Shares Acquired:
204,000 (Options), 136,000 (Restricted Stock Units)
Vesting Schedule:
Options vest one-fourth on 02/02/2027 and one thirty-sixth monthly thereafter; RSUs vest one-fourth each on 02/02/2027, 02/02/2028, 02/02/2029, 02/02/2030
Filing Date:
02/04/2026
Attorney:
Joseph Oliveto
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / City:
N/A
Topic:
ADHD, neurofeedback, cognitive approaches, classroom strategies
Document Type:
Template
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Students, educators, researchers, healthcare professionals
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Contextual Description:
Template for organizing annotated bibliography entries and comparing primary and secondary sources regarding ADHD treatments and strategies for managing symptoms.
Year:
2026
Region / City:
Not specified
Topic:
Attention deficit hyperactivity disorder (ADHD), Cognitive training, Mindfulness training
Document type:
Project template
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Students in psychology courses, educators, and professionals working with children with ADHD
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
[DATE]
Region / City:
[LOCATION]
Topic:
Preliminary Design Review, Engineering, Defense Systems
Document Type:
Executive Summary, Report
Organization / Institution:
[OFFICE CONDUCTING THE ASSESSMENT]
Author:
[NAME OF AUTHOR, IF AVAILABLE]
Target Audience:
Milestone Decision Authority, Program Management, Stakeholders
Period of Effectiveness:
[DATE]
Approval Date:
[DATE OF APPROVAL, IF AVAILABLE]
Date of Amendments:
[DATE, IF AVAILABLE]
Year:
2021
Region / City:
Australia
Topic:
Project reporting guidelines
Document Type:
Report
Organization / Institution:
MLA (Meat & Livestock Australia)
Author:
MLA
Target Audience:
Project managers, stakeholders, researchers
Period of validity:
N/A
Approval Date:
N/A
Date of changes:
April 2021
Year:
20xx
Note:
Project
Date:
04/01/20xx
Milestone Numbering:
Standard numbering format.
Completion Dates:
05/01/20xx, 06/10/20xx, 08/14/20xx, 10/09/20xx, 11/10/20xx, 12/01/20xx, 12/31/20xx
Document Type:
Template
Verification:
Sponsor Approval
Year:
2024
Region / City:
Dublin
Theme:
Housing Development, Urban Regeneration
Document Type:
Press Release
Organization:
Dublin City Council
Author:
Not specified
Target Audience:
General public, stakeholders in urban development
Period of Validity:
Until completion of the project in 2024
Approval Date:
10th April 2024
Date of Changes:
Not specified
Note:
Year
Contextual description:
Checklist for thesis progress and milestone documentation, including required components and details for milestone committee review.
Year:
2013
Document Type:
Memorandum
Organization:
Office of the Under Secretary of Defense for Acquisition, Technology, and Logistics (OUSD(AT&L))
Program:
[Program Name]
Audience:
Acquisition Professionals
Milestone:
Milestone A
Funding Direction:
Technology Development phase fully funded
References:
Defense Acquisition Guidebook (DAG) Chapter 3; Better Buying Power memoranda; 10 USC 2366a
MDA Certification:
Required by 10 USC 2366a
Approval:
MS A approval, ACAT designation, initial operational capability targets, exit criteria
Note:
Year
Organization:
Department of Defense
Document Type:
Program Assessment Checklist
Responsible Office:
OIPT Lead, Service Acquisition Executive, DJS/J-8, OUSD(C), CAPE, DASD(SE), ASD(R&E), DOT&E, DASD(DT&E), L&MR, DP&AP, OGC, OUSD(P), OUSD(P&R), OUSD(I), DoD CIO, IC, ARA
Approval Dates:
Various (per signature fields)
Program Focus:
Defense acquisition program
Scope:
Requirements, funding, risk, technology, testing, logistics, statutory compliance, training, information assurance, exportability
Year:
2021
Region / city:
United States
Theme:
Police Brutality, Law Enforcement, Race Relations
Document Type:
Research Paper
Institution:
N/A
Author:
Taylor Mahoney
Target Audience:
Students, Scholars of Law Enforcement and Social Issues
Period of Action:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Context:
Research paper discussing the perception of police brutality among different racial groups in the U.S., using surveys and polls to present data on public opinion regarding law enforcement practices.
Year:
2020
Location:
Washington, DC, USA
Subject:
Cardiac Electrophysiology and Device Therapy
Document Type:
Press Release
Organization:
International Board of Heart Rhythm Examiners (IBHRE)
Author:
Tracy Lofty
Anniversary:
35 Years
Event Date:
February 10, 2020
Video Release Date:
February 10, 2020
Video Series Launch:
March 16, 2020
Anniversary Reception:
May 2020 at Heart Rhythm Society Scientific Sessions, San Diego
Target Audience:
Cardiac Professionals and Healthcare Industry
Note:
Year
Course:
IT 7993 Capstone Project
Document Type:
Academic report guide
Milestone:
Milestone 3
Institutional Context:
Department IAB Meeting and Project Sponsor Site
Related Platform:
D2L
Submission Components:
Milestone 3 Report, PowerPoint Presentation, Updated Project Plan, Gantt Chart, Project Website
Evaluation Criteria:
Report completeness, team presentation performance, teamwork activities, project owner assessment, instructor evaluation
Grading Weight:
5% milestone report, 32.5% project owner assessment, 15% instructor evaluation
Meeting Duration:
60 minutes
Presentation Duration:
30 minutes
Required Format:
MS Word, Times New Roman 12pt, single spaced
Audience:
Project owner, instructor, student team members
Course Code:
IND 299
Module:
Module Two
Document Type:
Assignment Guidelines and Rubric
Academic Program:
Bachelor of Arts in General Studies (BA.GS)
Assignment Title:
Milestone One
Subject:
SMART Goal and Strategy Paper
Audience:
Students enrolled in the BA.GS degree program
Purpose:
Articulation of career and personal goals related to completion of the BA.GS degree
Submission Format:
1–2 page Microsoft Word document
Formatting Requirements:
Double spacing, 12-point Times New Roman font, one-inch margins
Evaluation Criteria:
Specific Goal; Measure; Attain; Relevance; Time Frame; Articulation of Response
Total Points:
100
Document type:
Questionnaire
Subject:
Milestone herbicide label analysis
Product name:
Milestone
Regulatory reference:
PCP number 28517
Topic:
Herbicide formulation, active ingredients, and application requirements
Intended audience:
Students or trainees in pesticide application
Geographical scope:
Not specified
Source type:
Educational assignment
Content focus:
Label interpretation and regulatory compliance
Year:
2025
Region / city:
Global
Topic:
Pharmaceuticals, Quality Guidelines
Document Type:
Guideline
Organization / Institution:
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
Author:
ICH Assembly
Target Audience:
Regulatory authorities, pharmaceutical industry
Period of validity:
Ongoing
Approval Date:
14 May 2025
Date of Changes:
Currently under public consultation
Note:
Context
Year:
2023
Region / City:
Australia
Subject:
Chronic migraine, medicinal product submission
Document type:
Submission for PBS listing
Organization:
Novartis Pharmaceuticals Australia Pty. Limited
Author:
Not specified
Target audience:
Health professionals, pharmaceutical regulatory bodies
Period of validity:
Not specified
Date of approval:
2 July 2018
Date of amendments:
November 2023
Year:
2023
Region / city:
Australia
Topic:
Vedolizumab submission for chronic pouchitis treatment
Document type:
Submission for listing of medicinal product
Agency:
Therapeutic Goods Administration (TGA)
Author:
Takeda Pharmaceuticals Australia Pty. Ltd.
Target audience:
Healthcare professionals, regulatory authorities
Effective period:
From 29 June 2023
Approval date:
29 June 2023
Modification date:
N/A
Year:
2022
Region / city:
Sri Lanka
Topic:
Pharmaceuticals import
Document type:
Invitation for expressions of interest
Organization:
Ministry of Health, Sri Lanka
Author:
Ministry of Health
Target audience:
Pharmaceutical suppliers
Period of validity:
3 months
Approval date:
27th September 2022
Date of amendments:
N/A
Year:
2018
Region / City:
Australia
Topic:
Pharmaceutical Submission, Cancer Treatment
Document Type:
Submission
Organization / Institution:
Takeda Pharmaceuticals Australia Pty Ltd
Author:
Takeda Pharmaceuticals Australia Pty Ltd
Target Audience:
Healthcare professionals, PBAC
Period of Validity:
Ongoing
Approval Date:
23 May 2018
Date of Amendments:
Not specified